Evidence map›Paper›PMID 38932243›Full record

ReviewViruses2024

Breakthrough Acute HIV Infections among Pre-Exposure Prophylaxis Users with High Adherence: A Narrative Review.

Davide Moschese, Samuel Lazzarin, Martina Laura Colombo, Francesco Caruso, Andrea Giacomelli, Spinello Antinori, Andrea Gori

Abstract readReview
In one paragraph

Review in Viruses, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Davide MoscheseI Division of Infectious Diseases, ASST Fatebenefratelli Sacco, Luigi Sacco Hospital, 20157 Milan, Italy.ORCID 0000-0001-5901-6742
Samuel LazzarinDepartment of Biomedical and Clinical Sciences, Università degli Studi di Milano, 20133 Milan, Italy.
Martina Laura ColomboDepartment of Biomedical and Clinical Sciences, Università degli Studi di Milano, 20133 Milan, Italy.
Francesco CarusoDepartment of Biomedical and Clinical Sciences, Università degli Studi di Milano, 20133 Milan, Italy.
Andrea GiacomelliDepartment of Biomedical and Clinical Sciences, Università degli Studi di Milano, 20133 Milan, Italy.ORCID 0000-0003-3685-4289
Spinello AntinoriDepartment of Biomedical and Clinical Sciences, Università degli Studi di Milano, 20133 Milan, Italy.ORCID 0000-0003-0569-9407
Andrea GoriI Division of Infectious Diseases, ASST Fatebenefratelli Sacco, Luigi Sacco Hospital, 20157 Milan, Italy.ORCID 0000-0001-6587-4794

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pre-exposure prophylaxis (PrEP) is a pivotal intervention among HIV prevention strategies. We aimed to narratively revise the topic of HIV acute infection in the setting of PrEP exposure with a focus on diagnostic options, clinical features, and future PrEP perspectives, with a particular focus on users with high adherence to PrEP. We searched the main databases (PubMed, Embase, and Scopus) with the keywords "PrEP" or "Pre-Exposure Prophylaxis" and "HIV" or "PLWH" and "breakthrough" or "acute infection" or "primary infection". We included all randomized clinical trials and non-experimental studies (both case reports and observational studies) ever published. In the present narrative review, we revise the diagnostic challenges related to HIV diagnosis in the setting of PrEP and the clinical characteristics and symptoms of breakthrough infections. We discuss the management of acute HIV infection during PrEP and the new challenges that arise from the use of long-acting drugs for PrEP. Our review underlines that although extremely rare, HIV seroconversions are still possible during PrEP, even in a context of high adherence. Efforts to promptly identify these events must be included in the PrEP follow-up in order to minimize the chance of overlooked HIV breakthrough infections and thus exposure to suboptimal concentrations of antiretrovirals.

Indexed as

Anti-HIV AgentsHIV InfectionsMedication AdherencePre-Exposure ProphylaxisHumansAnti-HIV AgentsadherencefailureHIVPrEPprimary HIV

Identifiers

PMID38932243
PMCPMC11209220

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.